Dabigatran
Pradaxa (dabigatran) is a small molecule pharmaceutical. Dabigatran was first approved as Pradaxa on 2008-03-17. It has been approved in Europe to treat replacement arthroplasty and venous thromboembolism. The pharmaceutical is active against prothrombin. Pradaxa's patents are valid until 2031-01-20 (FDA).
| Trade Name | Pradaxa |
|---|---|
| Common Name | Dabigatran |
| Indication | replacement arthroplasty, venous thromboembolism |
| Drug Class | Thrombin inhibitors (argatroban type) |
